Contributors
James L. Abbruzzese(Duke University), Michaele C. Christian(Walter Reed Army Institute of Research), Megan E. Anderson, Juliet L. Aylward, Therese B. Bevers(The University of Texas MD Anderson Cancer Center), Luiz H. Araujo, Julie R. Brahmer(Johns Hopkins University), Emmanuel S. Antonarakis(University of Minnesota), Stefan K. Barta(University of Pennsylvania), Michelle Alonso‐Basanta(University of Pennsylvania), Jennifer H. Choe(Vanderbilt University Medical Center), Ilene Browner, Jorge J. Castillo(Dana-Farber Cancer Institute), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Courtney J. Balentine, H. Ballentine Carter, Nai‐Kong V. Cheung(Memorial Sloan Kettering Cancer Center), Richard Aplenc(Children's Hospital of Philadelphia), John F. Boggess(University of Kentucky), Karen Basen‐Engquist, Vikash P. Chauhan(Massachusetts Institute of Technology), Herbert Chen(University of Alabama at Birmingham), Karen A. Cadoo(Trinity College Dublin), Claudia I. Chapuy(University of Göttingen), Dara L. Aisner(University of Colorado System), William R. Burns, Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Janet E. Brown(University of Sheffield), Karen Brown(University of Leicester), Jeffrey S. Abrams(National Cancer Institute), David P. Carbone(Vanderbilt University), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Eric L. Chang(Keck Hospital of USC), Janet L. Abrahm(Harvard University), Ammar Asban(Tufts University), Powel H. Brown(The University of Texas MD Anderson Cancer Center), Arjun Vasant Balar(NYU Langone Health), Paul A. Bunn(University of Colorado Denver), Donald A. Berry(Berry & Associates (United States)), Nancy L. Bartlett(Washington University in St. Louis), Ronald C. Chen(University of North Carolina at Chapel Hill), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Ross S. Berkowitz(Dana-Farber Brigham Cancer Center), Stephen J. Chanock(National Cancer Institute), Alfred E. Chang(University of Michigan), Jesús Anampa(Albert Einstein College of Medicine), John C. Byrd(The Ohio State University), Lynda K. Beaupin(Roswell Park Comprehensive Cancer Center), Edward R. Ashwood, Jeremy S. Abramson(Massachusetts General Hospital)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k